Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GC022F / AstraZeneca
NCT04626908: Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma	Not yet recruiting	1/2	18	RoW	GC022F CAR-T cells, GC022F CAR-T cells injection	He Huang, Gracell Biotechnology Ltd.	Relapsed and Refractory, Lymphoid Hematological Malignancies	06/22	06/23
NCT04412174: A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL	Not yet recruiting	1	18	RoW	GC022F	Hebei Yanda Ludaopei Hospital, Gracell Biotechnology Ltd.	B-cell Non Hodgkin Lymphoma	12/22	12/22